What FDA Requires by Country: China, India and Korea Exporters

FDA requirements follow the product category

FDA applies registration, listing, U.S. Agent, labeling, and premarket rules according to product category and facility activity, not according to whether the exporter is in China, India, or Korea. A Chinese and Korean medical-device manufacturer performing the same activities face the same core device requirements, just as Indian and Chinese drug establishments performing the same activities are governed by 21 CFR Part 207.

Country of manufacture still matters operationally. The manufacturer's exact firm and product may appear on an FDA Import Alert, a food importer's FSVP verification plan must account for supplier compliance history, FDA uses risk signals when selecting foreign facilities for inspection, and communications sent during U.S. business hours arrive overnight in Asia. FDA-regulated products made outside the United States must meet the same standards as domestic products, while inspection selection remains risk-based. FDA Inspection Basics

What stays the same and what changes by country

FDA requirements and operational variables for exporters in China, India, and Korea, checked October 29, 2026.
Decision point	Identical regardless of origin	What is origin-specific
Governing requirements	The product's intended use and the facility's activities determine whether food, drug, cosmetic, or medical-device rules apply. Country of manufacture does not create a separate FDA registration regime.	Local documents, business names, addresses, and identifiers must match the information submitted to FDA. Translation and time-zone coordination can affect how quickly discrepancies are resolved.
Registration, listing, and U.S. Agent	Foreign facilities complete the filings required for their category. Food facilities, foreign device establishments, foreign drug establishments, and registered foreign cosmetic facilities identify a U.S. Agent under their applicable systems. FDA device U.S. Agent requirements	The actual filing path reflects the products made at the site. India commonly raises Part 207 drug and API questions, Korea raises MoCRA skincare questions, and China spans food, devices, cosmetics, drugs, and ingredients.
Import Alert exposure	Only the firms, products, countries, or combinations covered by an alert's Red or Yellow List are subject to detention without physical examination. A country index entry is not a blanket ban on every exporter from that country. FDA Import Alerts	Current examples include Alerts 25-21, 89-16, 99-29, and 99-34 on the China index; Alerts 16-35, 66-40, 66-79, and 99-34 on the India index; and Alerts 25-21, 89-04, and 99-49 on the Korea index. These examples are not exhaustive.
FSVP verification for food	The U.S. FSVP importer evaluates hazards, supplier performance, FDA compliance history, and appropriate verification activities under 21 CFR 1.505 and 1.506.	A supplier's warning letters, Import Alert status, refusal history, audit results, and food-safety record can increase the documentation, sampling, testing, records review, or onsite auditing expected in the importer's program. FDA FSVP requirements
Inspection selection	FDA uses risk-based inspection selection rather than a separate inspection rule for each exporting country.	Product risk, manufacturing process, facility type, prior inspections, recalls, refusal history, compliance signals, and whether a foreign regulator has inspected the facility can change the likelihood and scope of an inspection. FDA risk-based inspection criteria
U.S. Agent confirmation clocks	The applicable confirmation period is determined by product category. A foreign device establishment's agent has 10 business days to confirm. A foreign food facility's agent confirmation must be completed within 30 calendar days of the registration submission.	FDA emails sent during U.S. business hours commonly arrive overnight in China, India, or Korea. An inactive mailbox or slow relay process can consume the confirmation period before the overseas team begins its next working day. FDA food facility registration instructions

How the answer changes for China, India, and Korea

Chinese manufacturers must start with product classification

China has no single FDA market-entry checklist because Chinese manufacturers export across several FDA categories. A food processor generally addresses food facility registration, a U.S. Agent, importer-side FSVP, labeling, and Prior Notice for each shipment. A device manufacturer addresses establishment registration, device listing, a U.S. Agent, applicable premarket authorization, and UDI or GUDID obligations. A cosmetics facility follows MoCRA, while a product marketed with therapeutic claims can enter the drug framework.

The practical first step is to classify each product by intended use and claims, then map every manufacturing, processing, packing, or holding location involved. A generic claim that a factory is “FDA registered” does not establish that each product is properly listed, cleared, approved, or prepared for import. The separate filing layers are explained in FDA facility registration versus product listing.

Indian pharmaceutical and API exporters follow 21 CFR Part 207

A foreign Indian establishment manufacturing, repacking, relabeling, or otherwise processing drugs for U.S. distribution must register before its drugs are offered for import. Establishment registration renews annually between October 1 and December 31. Drug registration and listing information is submitted electronically in Structured Product Labeling format, and changed listing information is updated in June or December. FDA drug establishment registration instructions

Registration and listing do not replace the product's approval, abbreviated application, OTC monograph, labeling, or current good manufacturing practice requirements. For an Indian API or finished-dose manufacturer, the operating file should connect the establishment registration, U.S. Agent, labeler code and NDC records, SPL documents, product authorization status, and current labels. FDA's India index currently includes drug-related Alerts 66-40 for firms that have not met drug GMPs and 66-79 for establishments refusing inspection, but DWPE applies according to the alert's named entries rather than Indian origin alone.

Korean skincare brands follow MoCRA, not a Korea-specific rule

A Korean facility that manufactures or processes cosmetics for U.S. distribution is subject to the same MoCRA framework as a facility in any other country. A covered foreign facility registers with FDA, identifies a U.S. Agent, updates material registration changes within 60 days, and renews every two years. The Responsible Person named on the product label submits each required cosmetic product listing and provides updates annually. FDA cosmetic registration and listing requirements

For a newly marketed cosmetic, section 607 gives the Responsible Person 120 days after marketing to submit the product listing. Completing the listing before launch is operationally cleaner because the facility, formula, ingredient, label, and Responsible Person records can be checked together. The MoCRA small-business exemption depends on the company's three-year U.S. cosmetic sales and its product types, not on Korean origin; eye-contact, injected, internal-use, and certain products that alter appearance for more than 24 hours remain outside that exemption.

What detention without physical examination means

Detention without physical examination, commonly shortened to DWPE, allows FDA to detain a covered shipment without first sampling or physically examining that individual entry. If a firm or product is on an alert's Red List, the importer must submit evidence that overcomes the appearance of the violation or the product can be refused admission.

The exact alert controls the response. Evidence can include private laboratory results, corrected registration or listing records, revised labels, manufacturing documentation, corrective actions, or other material required by the alert's Guidance section. Long-term removal from the Red List is separate from obtaining release of one detained shipment. The workflow is covered in FDA Import Alert removal and DWPE response.

The time-zone problem can cancel a registration

An FDA email sent at 4:00 p.m. Eastern reaches India at approximately 1:30 or 2:30 a.m. the next day, China at 4:00 or 5:00 a.m., and Korea at 5:00 or 6:00 a.m., depending on U.S. daylight saving time. India remains at UTC+5:30, China at UTC+8, and Korea at UTC+9 throughout the year. India time zone, China time zone, and Korea Standard Time

Medical devices have a 10-business-day confirmation window

The U.S. Agent for a foreign medical-device establishment must confirm the designation within 10 business days. If the agent does not respond, FDA cancels the receipt code, removes the agent information associated with the establishment, and requires a qualifying replacement. A device manufacturer cannot rely on an unmonitored address or wait for an overseas executive to review routine confirmation emails. FDA device agent confirmation instructions

Food registration has a 30-calendar-day confirmation window

FDA does not confirm a foreign food facility registration or issue the registration number until the designated U.S. Agent accepts. If the required action is not completed within 30 calendar days of the registration submission, FDA removes the registration information and a new submission is required. Weekends and Asian public holidays do not stop a calendar-day clock.

First FDA compliance sequence for any overseas exporter

Classify the product by intended use and claims. Determine whether it is food, a dietary supplement, cosmetic, drug, medical device, or a combination product before selecting a registration system.
Map every regulated facility and business role. Record the legal name, physical address, activities, products, owner, importer, label owner, and any existing FEI, DUNS, registration, listing, NDC, or device records.
Search FDA Import Alerts by firm and product. Review the exact manufacturer, shipper, product, and country entries. Do not treat the country index alone as proof that a shipment is subject to DWPE.
Designate an active U.S. Agent. Confirm that the agent can receive FDA communications during U.S. business hours and complete electronic acceptance within the category's deadline.
Complete the category-specific filings. This can include facility or establishment registration, product listing, SPL/XML, device listing, GUDID, cosmetic product listing, or applicable premarket submissions.
Align the importer-side obligations. Food shipments can require an FSVP importer and Prior Notice. Device imports involve an initial importer. Cosmetics require a Responsible Person for product-level MoCRA duties. These roles are not interchangeable with the U.S. Agent.
Check the label and shipment data before dispatch. The product description, manufacturer identity, claims, ingredients, listing records, and entry data should describe the same regulated product.

A new exporter can use the first FDA filing sequence to put registration, agent designation, listings, labeling, and shipment preparation in the correct order.

FDA Entry Point is a strong fit for Asian exporters when

A first-time exporter needs one U.S.-based contact to coordinate the correct registration, listing, label, and shipment sequence.
An Indian drug or API establishment needs U.S. Agent coverage alongside annual establishment registration, NDC listing, and SPL/XML support.
A Korean skincare business needs MoCRA facility registration, product listing, Responsible Person coordination, and INCI label review under one relationship.
A Chinese manufacturer operates across food, cosmetics, drugs, or medical devices and wants one compliance team rather than separate mailbox-only agents for each category.
The current U.S. Agent is slow to accept designations, relay FDA notices, explain deadlines, or coordinate inspection communications.

FDA Entry Point serves as an active U.S.-based FDA contact across food and beverage, cosmetics, drugs and pharmaceuticals, and medical devices. It receives and escalates official communications, coordinates agent-scope responses and inspection contacts, and commits to responses within 24 business hours. Registration, product listing, label review, Prior Notice, SPL, and GUDID/UDI services can be coordinated through the same team. FDA Entry Point U.S. Agent services

Frequently asked questions

I am a Chinese manufacturer. What is my first FDA compliance step?

Your first step is to classify the product by its intended use and U.S. marketing claims. That classification determines whether you follow food, drug, cosmetic, or medical-device requirements and which facilities, products, agents, importers, and labels must be filed or reviewed. After classification, search the live FDA Import Alert database for the exact manufacturer and product before completing registration or sending a commercial shipment.

What FDA requirements apply to an Indian pharmaceutical exporter?

An Indian pharmaceutical or API establishment subject to 21 CFR Part 207 must register before offering its drugs for U.S. import, identify one U.S. Agent, renew establishment registration annually from October 1 through December 31, and submit applicable drug listings electronically in SPL format. Listing changes are submitted in June or December. Registration does not replace product approval, OTC monograph compliance, labeling, or drug GMP obligations. FDA electronic drug registration and listing system

Do Korean skincare brands need MoCRA registration before selling in the United States?

Korean skincare facilities and Responsible Persons are subject to MoCRA on the same basis as other foreign cosmetics businesses. A covered manufacturing or processing facility must register, renew biennially, and identify a U.S. Agent. The Responsible Person must list each covered cosmetic and update the listing annually; a newly marketed product has a statutory 120-day listing period. Completing the filings before launch reduces mismatches between the facility, formula, label, and product listing.

Does an FDA country Import Alert mean every exporter from that country is detained?

No. An alert appearing on the China, India, or Korea country index does not automatically place every exporter from that country under DWPE. FDA applies each alert according to its scope and its Red, Yellow, or Green Lists. The firm name, facility, product, shipper, and country criteria must be checked against the live alert before deciding whether a shipment is covered.

Is a U.S. Agent the same as an FSVP importer or MoCRA Responsible Person?

No. A U.S. Agent is the FDA communication contact for a foreign facility. An FSVP importer performs or controls food supplier-verification duties under 21 CFR Part 1, while a cosmetic Responsible Person is the manufacturer, packer, or distributor whose name appears on the label and carries product-level MoCRA duties. A company can need more than one of these roles for the same market entry. FSVP importer versus FDA U.S. Agent

How does FDA Entry Point handle the time difference with Asia?

FDA Entry Point provides the U.S.-hours contact that FDA expects from an active agent. The team receives and escalates official communications, handles or coordinates the initial response within the U.S. Agent's scope, and relays the notice to the overseas manufacturer under a 24-business-hour response commitment. This operating model is especially useful when a device agent acceptance, food registration confirmation, inspection inquiry, or shipment notice arrives after the manufacturer's local business day.